Cargando…
Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer
Cancer cells often select for mutations that enhance signaling through pathways that promote anabolic metabolism(1). Although the PI3K/Akt signaling pathway, which is frequently dysregulated in breast cancer(2), is a well-established regulator of central glucose metabolism and aerobic glycolysis(3,4...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848114/ https://www.ncbi.nlm.nih.gov/pubmed/27088857 http://dx.doi.org/10.1038/ncb3341 |
_version_ | 1782429302696968192 |
---|---|
author | Lien, Evan C. Lyssiotis, Costas A. Juvekar, Ashish Hu, Hai Asara, John M. Cantley, Lewis C. Toker, Alex |
author_facet | Lien, Evan C. Lyssiotis, Costas A. Juvekar, Ashish Hu, Hai Asara, John M. Cantley, Lewis C. Toker, Alex |
author_sort | Lien, Evan C. |
collection | PubMed |
description | Cancer cells often select for mutations that enhance signaling through pathways that promote anabolic metabolism(1). Although the PI3K/Akt signaling pathway, which is frequently dysregulated in breast cancer(2), is a well-established regulator of central glucose metabolism and aerobic glycolysis(3,4), its regulation of other metabolic processes required for tumor growth is not well defined. Here we report that in mammary epithelial cells, oncogenic PI3K/Akt stimulates glutathione (GSH) biosynthesis by stabilizing and activating Nrf2 to up-regulate the GSH biosynthetic genes. Increased Nrf2 stability is dependent on the Akt-mediated accumulation of p21(Cip1/WAF1) and GSK-3 inhibition. Consistently, in human breast tumors, up-regulation of Nrf2 targets is associated with PI3K pathway mutation status and oncogenic Akt activation. Elevated GSH biosynthesis is required for PI3K/Akt-driven resistance to oxidative stress, initiation of tumor spheroids, and anchorage-independent growth. Furthermore, inhibition of GSH biosynthesis with buthionine sulfoximine (BSO) synergizes with cisplatin (CDDP) to selectively induce tumor regression in PI3K pathway mutant breast cancer cells, both in vitro and in vivo. Our findings provide insight into GSH biosynthesis as a metabolic vulnerability associated with PI3K pathway mutant breast cancers. |
format | Online Article Text |
id | pubmed-4848114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-48481142016-10-18 Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer Lien, Evan C. Lyssiotis, Costas A. Juvekar, Ashish Hu, Hai Asara, John M. Cantley, Lewis C. Toker, Alex Nat Cell Biol Article Cancer cells often select for mutations that enhance signaling through pathways that promote anabolic metabolism(1). Although the PI3K/Akt signaling pathway, which is frequently dysregulated in breast cancer(2), is a well-established regulator of central glucose metabolism and aerobic glycolysis(3,4), its regulation of other metabolic processes required for tumor growth is not well defined. Here we report that in mammary epithelial cells, oncogenic PI3K/Akt stimulates glutathione (GSH) biosynthesis by stabilizing and activating Nrf2 to up-regulate the GSH biosynthetic genes. Increased Nrf2 stability is dependent on the Akt-mediated accumulation of p21(Cip1/WAF1) and GSK-3 inhibition. Consistently, in human breast tumors, up-regulation of Nrf2 targets is associated with PI3K pathway mutation status and oncogenic Akt activation. Elevated GSH biosynthesis is required for PI3K/Akt-driven resistance to oxidative stress, initiation of tumor spheroids, and anchorage-independent growth. Furthermore, inhibition of GSH biosynthesis with buthionine sulfoximine (BSO) synergizes with cisplatin (CDDP) to selectively induce tumor regression in PI3K pathway mutant breast cancer cells, both in vitro and in vivo. Our findings provide insight into GSH biosynthesis as a metabolic vulnerability associated with PI3K pathway mutant breast cancers. 2016-04-18 2016-05 /pmc/articles/PMC4848114/ /pubmed/27088857 http://dx.doi.org/10.1038/ncb3341 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Lien, Evan C. Lyssiotis, Costas A. Juvekar, Ashish Hu, Hai Asara, John M. Cantley, Lewis C. Toker, Alex Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer |
title | Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer |
title_full | Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer |
title_fullStr | Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer |
title_full_unstemmed | Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer |
title_short | Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer |
title_sort | glutathione biosynthesis is a metabolic vulnerability in pi3k/akt-driven breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848114/ https://www.ncbi.nlm.nih.gov/pubmed/27088857 http://dx.doi.org/10.1038/ncb3341 |
work_keys_str_mv | AT lienevanc glutathionebiosynthesisisametabolicvulnerabilityinpi3kaktdrivenbreastcancer AT lyssiotiscostasa glutathionebiosynthesisisametabolicvulnerabilityinpi3kaktdrivenbreastcancer AT juvekarashish glutathionebiosynthesisisametabolicvulnerabilityinpi3kaktdrivenbreastcancer AT huhai glutathionebiosynthesisisametabolicvulnerabilityinpi3kaktdrivenbreastcancer AT asarajohnm glutathionebiosynthesisisametabolicvulnerabilityinpi3kaktdrivenbreastcancer AT cantleylewisc glutathionebiosynthesisisametabolicvulnerabilityinpi3kaktdrivenbreastcancer AT tokeralex glutathionebiosynthesisisametabolicvulnerabilityinpi3kaktdrivenbreastcancer |